Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Reference7 articles.
1. Mylan GmbH. FULPHILA™ (pegfilgrastim-jmdb) injection, for subcutaneous use: US prescribing information. 2018.
http://www.fda.gov/
. Accessed 11 Oct 2018.
2. Mylan S.A.S. Fulphila 6 mg solution for injection in pre-filled syringe: EU summary of product characteristics. 2018.
https://www.ema.europa.eu/
. Accessed 12 Dec 2018.
3. Waller CF, Tiessen RG, Lawrence TE, et al. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin Oncol. 2018;144(6):1087–95.
4. Sankaran PK, Palanivelu DV, Nair R, et al. Characterization and similarity assessment of a pegfilgrastim biosimilar MYL-1401H. J Clin Oncol. 2018;36(15 Suppl):e19028.
5. US FDA. Center for Drug Evaluation and Research application number 761075Orig1s000: clinical review(s). 2018.
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761075Orig1s000MedR.pdf
. Accessed 12 Nov 2018.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献